Financial Results
Centenial Surgical Suture Publishes Q2 FY27 Results
Centenial Surgical Suture published standalone unaudited results for the quarter and half year ended September 30, 2026, reporting quarterly profit after tax of Rs. 68.75 lakh.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
6
Neutral
4
Bullish
4
Bearish
10
Neutral
8
Bullish
28
Bearish
4
Neutral
4
Bullish
24
Bearish
4
Neutral
4
Bullish
24
Bearish
4
Neutral
4
Bullish
24
Bearish
4
Neutral
4
Bullish
24
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Financial Results
Centenial Surgical Suture published standalone unaudited results for the quarter and half year ended September 30, 2026, reporting quarterly profit after tax of Rs. 68.75 lakh.
Financial Results
Centenial Surgical Suture approved standalone unaudited results for the quarter and half year ended September 30, 2026, recorded a director’s resignation, and approved an independent assessment of fundraising options.
Centenial Surgical Suture Ltd (CSURGSU) is currently trading at 86.94 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Centenial Surgical Suture Limited manufactures and sells surgical sutures and related cardiovascular consumables, including absorbable and non-absorbable sutures, atraumatic needles, titanium haemostatic clips, temporary pacemaker electrodes and female urinary incontinency sets; the company operates a manufacturing facility in MIDC Murbad (Thane), emphasizes cardiovascular applications, and holds multiple ISO certifications and WHO GMP compliance. Latest unaudited results for quarter and half year ended September 30, 2025 show revenue from operations of Rs. 1,345.50 lakhs for the quarter and Rs. 2,639.11 lakhs for the half year, with a marginal loss before tax of Rs. 5.11 lakhs for the half year, indicating near break-even operations and tight operating margins. Operating cash flow for the half year is negative at Rs. (84.67) lakhs while the company reports significant ‘other current financial assets’ of Rs. 6,293.42 lakhs and inventory of Rs. 1,984.92 lakhs, indicating substantial short-term financial placements alongside elevated working capital in manufactured goods and stocks. Centenial differentiates through deep cardiovascular sutures know‑how, a catalogue of over 300 product codes for CABG and atraumatic needle design, continuous R&D, surgeon collaboration and multiple quality accreditations (ISO 9001, ISO 13485, ISO 14001, ISO 45001 and WHO GMP) positioning it as a trusted domestic supplier for specialised surgical applications.
Over the past 52 weeks, Centenial Surgical Suture Ltd has traded between a low of ₹66.60 and a high of ₹124.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Centenial Surgical Suture Ltd has a market capitalization of approximately 31.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Centenial Surgical Suture Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -43.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 31.72 Cr, Centenial Surgical Suture Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Centenial Surgical Suture Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Centenial Surgical Suture Ltd is -43.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Centenial reported a net profit of Rs 142.26 lakh for the half year ended September 30, 2026. It had reported a Rs 5.11 lakh loss for the corresponding half year ended September 30, 2025.
Centenial Surgical Suture Ltd reported standalone net profit of ₹0.74 crore for the quarter ended June 30, 2026. It had recorded a net loss of ₹0.04 crore in the corresponding quarter of the previous financial year.
The company said unusual small-lot trades and price movements in its shares were not supported by material corporate announcements and could indicate manipulation.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
32 Cr
Low Risk
-43.5
60.1
—
1.1
124.90
66.60
Sales CAGR
Profit CAGR
ROE
ROCE
